XSHG
603590
Market cap740mUSD
Oct 09, Last price
30.98CNY
1D
-0.67%
1Q
-2.98%
IPO
-43.50%
Name
Beijing Konruns Pharmaceutical Co Ltd
Chart & performance
P/E
29.68
P/S
5.38
EPS
1.04
Div yield, %
1.92%
Shrs. gr., 5y
-0.05%
Rev. gr., 5y
2.50%
Revenues
915m
+10.87%
Net income
166m
+293.13%
CFO
116m
-32.84%
Dividend
Jul 08, 20260.35 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Beijing Konruns Pharmaceutical Co.,Ltd., a Chinese company established in 2003 and based in Beijing, focuses on the discovery, production, and distribution of various pharmaceutical items. Among its key offerings is Su Ling, a hemagglutinin preparation designed to minimize blood loss during surgical procedures and manage post-operative bleeding. The firm is also actively developing a pipeline of potential new medicines, such as CX1026, CX1003, and KC1036.
Key people
Xiaodong Huang
Secretary of the Board · since 2025
Jin Li
Director
Xiaohan Liu
Chief Financial Officer, Director · since 2025
Jianhua Liu
Chairman of the Board · since 2025
President, Director · since 2024
Xijuan Wang
Director · since 2023
Independent Director · since 2021
Junyan Liu
Independent Director · since 2025
Independent Director · since 2025
Yonggong Zhai
Independent Director · since 2021
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||